Research programme: chimerasome nanocage therapeutics - Eloxx Pharmaceuticals

Drug Profile

Research programme: chimerasome nanocage therapeutics - Eloxx Pharmaceuticals

Alternative Names: CH 001; SVN-003

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fabrus
  • Developer Eloxx Pharmaceuticals
  • Class Antibodies; Insulins; Pancreatic hormones; Peptides; Proteins; Small interfering RNA; Small molecules
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
  • 24 Nov 2014 Sevion Therapeutics enters into a research agreement with Avidity NanoMedicines LLC regarding the use of Sevion's chimerasome technology to deliver nucleic acids
  • 09 Sep 2014 Senesco Technologies changes name to Sevion Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top